Paradigm Biopharmaceuticals Limited

ASX:PAR Stock Report

Market Cap: AU$131.0m

Paradigm Biopharmaceuticals Future Growth

Future criteria checks 0/6

Paradigm Biopharmaceuticals's earnings are forecast to decline at 13.2% per annum. EPS is expected to grow by 23.2% per annum.

Key information

-13.2%

Earnings growth rate

23.2%

EPS growth rate

Biotechs earnings growth15.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated28 Nov 2024

Recent future growth updates

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22
Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17
Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22
Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24
We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28
Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29
When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Earnings and Revenue Growth Forecasts

ASX:PAR - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024N/A-59-66-66N/A
3/31/20240-64-72-72N/A
12/31/20230-69-78-78N/A
9/30/20230-60-62-62N/A
6/30/2023N/A-52-45-45N/A
3/31/20230-48-39-39N/A
12/31/20220-44-33-33N/A
9/30/20220-42-33-33N/A
6/30/20220-39-32-32N/A
3/31/20220-40-32-32N/A
12/31/20210-41-32-32N/A
9/30/20210-37-34-34N/A
6/30/20210-34-35-35N/A
3/31/20210-31-29-29N/A
12/31/2020-1-28-24-23N/A
9/30/20200-20-17-17N/A
6/30/2020N/A-12-10-10N/A
3/31/20202-14-10-10N/A
12/31/20194-16-10-10N/A
9/30/20193-16-8-8N/A
6/30/20193-16-6-6N/A
3/31/20193-11-7-7N/A
12/31/20183-7-7-7N/A
9/30/20183-7-6-6N/A
6/30/20183-6-6-6N/A
3/31/20182-6N/A-4N/A
12/31/20172-5N/A-3N/A
9/30/20172-5N/A-4N/A
6/30/20172-4N/A-4N/A
3/31/20172-4N/A-5N/A
12/31/20161-4N/A-6N/A
9/30/20161-4N/A-5N/A
6/30/20161-3N/A-4N/A
3/31/20161-3N/A-3N/A
12/31/20150-2N/A-1N/A
9/30/20150-2N/A-1N/A
6/30/2015N/A-2N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PAR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PAR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PAR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if PAR's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if PAR's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PAR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 08:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Paradigm Biopharmaceuticals Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Soo RomanoffEdison Investment Research
Arron AatkarEdison Investment Research